Journal: The EMBO Journal
Article Title: Annexin A5 controls VDAC1-dependent mitochondrial Ca 2+ homeostasis and determines cellular susceptibility to apoptosis
doi: 10.1038/s44318-025-00454-9
Figure Lengend Snippet: ( A ) Bar graphs show the basal [Ca 2+ ] Matrix , ( B ) [Ca 2+ ] IMS, and ( C ) [Ca 2+ ] Cyto level in WT (black) and AnxA5-KO (red) cells upon 12 h DMSO, 5 μM and 10 μM cisplatin treatment. Data points represent the mean ± SEM for [Ca 2+ ] Matrix (n WT-DMSO = 63/6; n AnxA5-KO-DMSO = 75/6, n WT-5μM-cisplatin = 67/6; n AnxA5-KO-5μM-cisplatin = 71/6, n WT-10μM-cisplatin = 53/6; n AnxA5-KO-10μM-cisplatin = 54/6), and for [Ca 2+ ] IMS (n WT-DMSO = 64/6; n AnxA5-KO-DMSO = 66/6, n WT-5μM-cisplatin = 60/6; n AnxA5-KO-5μM-cisplatin = 74/6, n WT-10μM-cisplatin = 64/6; n AnxA5-KO-10μM-cisplatin = 63/6), and [Ca 2+ ] Cyto (n WT-DMSO = 64/6; n AnxA5-KO-DMSO = 68/6, n WT-5μM-cisplatin = 74/6; n AnxA5-KO-5μM-cisplatin = 84/6, n WT-10μM-cisplatin = 55/6; n AnxA5-KO-10μM-cisplatin = 83/6). The p -values for ( A ), from left to right, are: p = 0.3780 (ns), p = 0.0320 (* p < 0.05), and p = 0.0022 (** p < 0.01); for ( B ): p = 0.9716 (ns), p = 0.0640 (ns), and p = 0.0039 (** p < 0.01). ( D ) Bar graphs show the percentage of living cells and ( E ) late apoptosis, assessed by Annexin5-FITC/PI staining and FACS analysis in WT (black) and AnxA5-KO (red) cells upon 24 h DMSO, 5 μM and 10 μM cisplatin treatment. ( F ) Bar graphs show the percentage of living cells and ( G ) late apoptosis in WT (black) and AnxA5-KO (red) cells upon 24 h DMSO, 20 μM VBIT-4, 10 μM cisplatin, and cisplatin+VBIT-4 treatment. Data points represent the mean ± SEM (n WT-DMSO = 5; n AnxA5-KO-DMSO = 6, n WT-20μM-VBIT-4 = 6; n AnxA5-KO-20μM-VBIT-4 = 6, n WT-10μM-cisplatin = 6; n AnxA5-KO-10μM-cisplatin = 6, n WT-cisplatin+VBIT-4 = 6; n AnxA5-KO-cisplatin+VBIT-4 = 6). The p -values for ( D ), from left to right, are: p = 0.1775 (ns), p = 0.0043 (** p < 0.01), and p = 0.0095 (** p < 0.01); for ( E ): p = 0.6040 (ns), p = 0.0028 (** p < 0.01), and p < 0.0001 (**** p < 0.0001); for ( F ): p = 0.6787 (ns), p = 0.0582 (ns), p = 0.0037 (** p < 0.01), and p < 0.0001 (**** p < 0.0001); for ( G ): p = 0.8063 (ns), p = 0.1840 (ns), p < 0.0001 (**** p < 0.0001), and p < 0.0001 (**** p < 0.0001). ( H ) Representative immunoblot shows monomeric and dimeric VDAC1 levels. Uncropped blots are provided in the Source Data. ( I ) Bar graph shows the quantification of the immunoblot in WT (black) and AnxA5-KO (red) cells upon 48 h DMSO, 20 μM VBIT-4, 10 μM cisplatin, and cisplatin+VBIT-4 treatment (each color represents the experiments from the same day). Data points represent the mean ± SEM (n WT-all = 4; n AnxA5-KO-all = 4). The p -values, from left to right, are: p = 0.0003 (*** p < 0.001), p = 0.0037 (** p < 0.01), p = 0.0001 (*** p < 0.001), and p = 0.0005 (*** p < 0.001). n represents the number of cells/biological replicates (minimum of 3 independent experiments). Significant differences were assessed using either one-way ANOVA with Tukey’s multiple comparison tests (** p < 0.01, *** p < 0.001 and ns: not significant) and with the two-tailed unpaired Student’s t-test or Kolmogorov–Smirnov test (* p < 0.05, ** p < 0.01, **** p < 0.0001 and ns: not significant). .
Article Snippet: VDAC1 siRNA (5′-3′) ACACUAGGCACCGAGAUUA , Microsynth , Waldeck-Weiermair et al ( ) (Front Cell Neurosci) .
Techniques: Staining, Western Blot, Comparison, Two Tailed Test